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BI OF IRESSA IN NSCLC IN THE NETHERLANDS: A HOSPITAL 
PERSPECTIVE
Langenfeld M, Scheer F
AstraZeneca BV, Zoetermeer, The Netherlands
OBJECTIVES: To gain insight in the total Costs of ﬁ rst-line treatment of NSCLC 
phase III/IV in the Dutch hospital setting. To calculate the budget impact of adding 
Iressa (geﬁ tinib), including EGFR mutation testing, to the treatment sequence. To 
identify costs of EGFR mutation testing. METHODS: A budget impact model was 
constructed by Medaxial and adapted by AstraZeneca the The Netherlands to better 
reﬂ ect the Dutch situation. The model calculates the budget impact of EGFR testing 
and the resulting therapy change for NSCLC patients in Dutch hospitals. The model 
covers the ﬁ rst-line treatment of NSCLC fase IIIb/IV patients and calculates total costs 
in a hospital setting and budget impact, taken into account the following costs—Medi-
cation—EGFR mutation testing—Administration and monitoring—Treating grade III/
IV adverse events. The model also calculates—Costs of delivery of oral therapies 
(outside hospital costs). RESULTS: Before introduction of Iressa, total costs of ﬁ rst-
line NSCLC treatment in Dutch hospitals was c41,982.936. After introduction of 
Iressa, total costs in hospital setting slightly decreased to c41.939,604 (year 1). Cost 
of EGFR mutation testing is c198,432, but medication costs of the hospital will 
decrease with c248,193. CONCLUSIONS: Adding extra diagnosis will introduce new 
costs to the NSCLC treatment. However, for an individual hospital, the extra costs 
are limited. And the total costs of ﬁ rst-line NSCLC treatment even decrease, since the 
reimbursement of Iressa is outside of the hospital budget. As a result, the hospital has 
less costs if patients are tested and the appropriate patients then treated with Iressa. 
At the moment, for some hospitals, EGFR mutation testing is still seen as a hurdle. 
Apart from the ethical point of view (making sure patients will receive the medication 
they will beneﬁ t most from), also from costs perspective, it is worth to test.
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INFLUENCE OF ME-TOOS TO POSSIBLE SAVINGS DUE TO 
BIOSIMILARS
Fuezi J, Reichardt B
Sickness Fund Burgenland, Eisenstadt, Burgenland, Austria
OBJECTIVES: To avoid the waste of market shares, me-toos of established top-selling 
biopharmaceuticals enter the market before their patent expiry. After switching the 
sales to the me-too, called “step-innovation” by the provider, the possible savings of 
biosimilars diminish as the sales are parked at the me-toos. The objective of the study 
is to analyze this hypothesis for the two2 substance classes erythropoiesis-stimulating 
agents (ESA) and granulocyte colony-stimulating factors (G-CSF). METHODS: By 
analyzing the account data of regional Austrian sickness funds, the share of prescrip-
tions of ﬁ lgrastim in GCSF (ﬁ lgrastim plus lenograstim plus pegﬁ lgrastim) and of 
epoetin in ESA (epoetin plus darbepoetin) are correlated to the costs per package. 
These data are shown for several periods, 6 months before the availability of Biosimi-
lars, 6 montha after their availability, and 2 further half-years for ESA. To take 
regional inﬂ uence into consideration, the data are shown for all nine regional sickness 
funds of Austria. RESULTS: The shares of prescription for epoetin in ESA show a 
huge regional dispersion from 42% to 88% and those of ﬁ lgrastim in GCSF from 
23% to 66%. The average costs per package have an inverse relation to their market 
share. These data are reconﬁ rmed through data of the other periods. The average costs 
per package have been declined with increased market share of the biosimilars. The 
inﬂ uence of the market share of the me-toos is though overwhelming. CONCLU-
SIONS: For pharmaceutical companies, it is a proﬁ t-maximizing strategy to substitute 
their products in time before patent expiry. The less the substitution by patent-pro-
tected alternatives succeeds, the higher the achievable cost saving potential for the 
sickness funds is.
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COST UTILITY OF HUMAN PAPILOMA VIRUS VACCINE IN SPAIN
Callejo D, Lopez-Polin A, Blasco JA
Agencia Lain Entralgo, Madrid, Spain
OBJECTIVES: It is well known that a persistent infection by human papillomavirus 
(HPV) is an essential cause of cervical cancer. Prophylactic HPV vaccines aimed at 
preventing precancerous cervical lesions and cervical cancer are currently available 
and may be used for primary prevention of cervical cancer. To deﬁ ne the efﬁ ciency 
of using HPV vaccine within a cervical cancer screening program with cytology com-
pared with the strategy of only screening with cytology. METHODS: A comprehensive 
search of studies was developed in the main electronic databases including primary 
studies assessing HPV vaccine efﬁ cacy and/or safety or HPV. Meta-analysis was 
conducted when the studies were homogeneous. a decision analysis was performed 
using a Markov model based on the results of the systematic review and information 
about the natural history of the disease (HPV infection, cervical cancer). The model 
allowed to estimate cancer incidence and associated mortality, life expectancy, and 
associated costs, with the objective of performing an economic evaluation. RESULTS: 
A total of 11 studies were included to assess HPV vaccines: seven for efﬁ cacy and 11 
for safety assessment. The efﬁ cacy of vaccine in preventing CIN2+ was 96% (95% 
CI: 91% to 98%). Modiﬁ ed intention-to-treat and intention-to-treat analyses were 
also undertaken and the results supported this trend, although efﬁ cacy was lower. The 
economic evaluation showed that the vaccination strategy would imply a cost-effec-
tiveness ratio of around c10,000 per quality-life adjusted-years (QALY). CONCLU-
SIONS: There is evidence from RCTs that the HPV vaccines are safe and effective in 
the prevention of cervical cancer precursor lesions. On top of this, this efﬁ cacy is 
reached with a reasonable cost-effectiveness ratio and within the accepable limits of 
the Spanish National Health System.
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COST ANALYSIS OF MANAGING ADVERSE EVENTS IN THE 
TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN 
PORTUGAL: A COMPARISON OF BEVACIZUMAB IN COMBINATION 
WITH INTERFERON ALFA-2A AND SUNITINIB
Silva CI1, Monteiro I2, Schwander B3
1Eurotrials Scientiﬁ c Consultants, Lisbon, Portugal; 2Roche Farmacêutica Química, Amadora, 
Portugal; 3AiM GmbH—Assessment in Medicine, Research and Consulting, Lörrach, 
Germany
OBJECTIVES: The burden of metastatic renal cell carcinoma (mRCC) is substantial 
for patients and society. Bevacizumab (BEV) combination with interferon alfa-2a 
(IFN) has demonstrated to prolong mRCC patients’ progression-free survival and to 
have comparable efﬁ cacy to sunitinib (SUN). However, tolerability differs between 
these treatment alternatives and it is therefore of importance to evaluate the economic 
impact of adverse events (AEs) management, for each alternative, in the daily clinical 
practice in Portugal. METHODS: A linear decision analytical model was applied 
considering direct medical costs only in the Portuguese Health System perspective. AEs 
incidences associated with each of the two alternatives were extracted from published 
literature. Health resource consumption was estimated based on an expert panel of 
Portuguese oncologists and urologists. Corresponding unitary costs were obtained 
through national ofﬁ cial sources. The considered time horizon was 1 year. The base-
case analysis includes all grades AEs and a normal dose (nine MUI, three times weekly) 
of IFN scenario. Deterministic univariate sensitivity analyses were performed to test 
the robustness of the model including grade 3–4 AEs analysis only and IFN low-dose 
(six MUI or three MUI, three times weekly) scenarios. RESULTS: The associated costs 
of managing AEs were considerably lower with BEV + IFN than with SUN in Portugal. 
The average treatment costs for all grade AEs per patient was c1472 for SUN and 
c1093 for BEV + IFN resulting in a difference of −379 c (a cost saving of 26% for 
BEV + IFN vs. SUN). Sensitivity analyses showed that BEV + IFN remains the less 
costly option when alternative scenarios are considered and that a low-dose IFN would 
lead even to further cost savings. CONCLUSIONS: BEV + IFN is a more tolerable 
and hence cost-saving alternative for the Portuguese Health System considering the 
AE management costs of mRCC treatment when compared to SUN. These results are 
consistent with previous evidence for other countries.
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ECONOMIC OUTCOMES AMONG 2ND LINE NON-SMALL CELL LUNG 
CANCER PATIENTS IN THE OUTPATIENT COMMUNITY SETTING
Gruschkus S1, Reyes C2, Forsyth M1, Ravelo A2, Nadler E1
1US Oncology, The Woodlands, TX, USA; 2Genentech, Inc., South San Francisco, CA, USA
OBJECTIVES: Second-line monotherapy options for advanced NSCLC include erlo-
tinib (E), docetaxel (D), or pemetrexed (P). The purpose of this retrospective study 
was to compare economic outcomes among patients (pts) receiving 2nd line mono-
therapy in the outpatient community setting. METHODS: Using US Oncology’s 
iKnowMed EMR data, we identiﬁ ed advanced NSCLC patients who received 2nd line 
monotherapy from July 1, 2006 to June 30, 2008. Economic outcomes were derived 
using outpatient claims and pharmacy data and included total outpatient, chemo-
therapy, supportive care costs, and frequency of outpatient physician visits, lab pro-
cedures, and acute care (ER/inpatient) visits. All economic outcomes were calculated 
as per-patient month (PPM) metrics over a 12-month follow-up period. Multiple 
regression analyses were used to estimate the independent association between treat-
ment (E, D, or P) on outcomes after controlling for age, gender, stage at diagnosis, 
baseline hemoglobin, and performance status. RESULTS: We identiﬁ ed 610 pts—73 
received E, 87 received D, and 450 received P. Total cost, chemotherapy costs, and 
supportive care costs differed signiﬁ cantly by treatment, as did frequency of outpatient 
visits and lab procedures. Relative to P, total adjusted costs PPM is $1579 lower for 
D and $1584 lower for E (P < 0.05). Majority of the cost savings are due to decreased 
chemo-related costs. Outpatient visits, lab procedures, and acute care visits are also 
less frequent with E relative to P (−2.6 PPM, P < 0.05). CONCLUSIONS: In US 
outpatient setting, pts receiving E and D have statistically signiﬁ cant lower costs and 
resource use relative to pts receiving P.
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COSTS OF MANAGING ADVERSE EVENTS OF FIRST-LINE THERAPY 
FOR METASTATIC RENAL CELL CARCINOMA IN MEXICO: 
BEVACIZUMAB IN COMBINATION WITH INTERFERON-ALPHA-2A 
COMPARED WITH SUNITINIB
Carlos F, Ramirez J, Aguirre A
R a C Salud Consultores S.A. de C.V., México, D.F., Mexico
OBJECTIVES: Bevacizumab plus interferon-α2a (BEV+IFN) prolongs progression-
free survival (PFS) to >10 months, providing comparable efﬁ cacy to sunitinib in 
patients with metastatic renal cell carcinoma (mRCC). However, the type and fre-
quency of adverse events (AE) differ between these two regimens. We aimed to assess 
the costs of managing AE of grade 3/4 of these regimens from the perspective of public 
health-care system in Mexico. METHODS: A linear decision analytic model was 
developed to compare the direct medical costs of managing AE of grade 3/4 of BEV 
+ IFN and sunitinib in patients with mRCC. AE of grade 1/2 are assumed to entail 
